Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2286 • ACR Convergence 2024
Certolizumab Inhibits Radiographic Progression Even in RA Patients with High Rheumatoid Factor Levels: A Pooled, Post-Hoc Analysis of Two Phase 3 Trials
Josef Smolen¹, Gerd Burmester², Yoshiya Tanaka³, Tsutomu Takeuchi⁴, Jeffrey Curtis⁵, Ted Mikuls⁶, Clementina López Medina⁷, Peter C. Taylor⁸, Nicola Tilt⁹, Bernard Lauwerys¹⁰, Baran Ufuktepe¹¹ and Thomas Huizinga¹², ¹Medical University of Vienna, Vienna, Austria, ²Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁴Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁵The University of Alabama at Birmingham, Birmingham, AL, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Reina Sofia University Hospital, Cordoba, Spain, ⁸University of Oxford, Oxford, United Kingdom, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹UCB Pharma, Istanbul, Turkey, ¹²Department of Rheumatology, Leiden University, Leiden, Netherlands
Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), including those treated with disease-modifying antirheumatic drugs, high rheumatoid factor (RF) levels are a poor prognostic factor,…
Abstract Number: 2596 • ACR Convergence 2024
Clock Gene Bmal1 Contributes to Inflammation via Phosphorylation of NF-κB/p65 in RA-FLS
Hikari Tsukamoto¹, Kenta Kaneshiro¹, Kohsuke Yoshida¹, Koji Tateishi², Yasuhiro Terashima², Nao Shibanuma³, Yoshitada Sakai⁴ and Akira Hashiramoto¹, ¹Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan, ²Hakuhokai Kakogawa Hospital, Kakogawa, Hyogo, Japan, ³Kobe Kaisei Hospital, Kobe, Hyogo, Japan, ⁴Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
Background/Purpose: Inflammatory cytokines such as TNF-α, IL-6, and IFN-γ show their peaks at midnight in sera of patients with rheumatoid arthritis (RA), which is thought…
Abstract Number: PP03 • ACR Convergence 2024
How Completing a Systematic Literature Review Improved How I Research My Own Rheumatoid Arthritis and Comorbidities
Shelley Fritz, Global Healthy Living Foundation, Kalaheo, HI
Background/Purpose: Twelve years ago, I was diagnosed with rheumatoid arthritis (RA). Initially, I was hopeful that the first biologic DMARD would slow the disease and…
Abstract Number: 0033 • ACR Convergence 2024
Refined Autoantibody Profiles in RA Reveal That Primarily ACPAs Binding Non-glycine Citrulline Motifs Are Associated with Shared Epitope Alleles
Linda Mathsson-Alm¹, Helga Westerlind², Isabel Gehring³, Monika Hansson², Nasim Ghasemzadeh¹, Jessica Rojas-Restrepo³, Saedis Saevarsdottir⁴, Joseph Sexton⁵, Siri Lillegraven⁶, Espen Haavardsholm⁶, Merete Hetland⁷, Hilde Hammer⁸, Tore K. Kvien⁹, Bente Glintborg¹⁰, Leonid Padyukov², Johan Askling² and Caroline Grönwall², and the Danish Rheumatologic Biobank Study Group (the Biomarker Protocol), Swedish Rheumatology Quality Register Biobank Study Group (SRQb), ¹Thermo Fisher Scientific, Uppsala, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Thermo Fisher Scientific, Freiburg, Germany, ⁴University of Iceland, Reykjavik, Iceland, ⁵Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ⁸Diakonhjemmet Hospital, Oslo, Oslo, Norway, ⁹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁰DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: Carriage of HLA-DRB1 shared epitope (SE) alleles and a history of smoking, have been identified as the most prominent risk factors for development of…
Abstract Number: 0049 • ACR Convergence 2024
Inflammatory Priming by Anti-MAA Antibodies in Rheumatoid Arthritis
Marcelo Afonso¹, Jitong Sun¹, Koji Sakuraba¹, Alexandra Circiumaru², Denis Lagutkin¹, Masa Filipovic¹, Anca Catrina¹, Caroline Grönwall¹, Aase Hensvold¹ and Bence Réthi¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm region, Stockholm, Sweden
Background/Purpose: We have previously shown that autoantibodies targeting malondialdehyde-acetaldehyde protein adducts (anti-MAA) in rheumatoid arthritis (RA) patients boosted osteoclast differentiation and induced bone erosion in mice…
Abstract Number: 0079 • ACR Convergence 2024
Characterization of the Tissue Resident Memorial T Cells in Autoimmune Arthritis: A Comparative Study of Psoriatic Arthritis and Rheumatoid Arthritis
Siba Raychaudhuri¹, Christine Abria² and Smriti K Raychaudhuri³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²VA Medical Center Sacramento, Mather, CA, ³VA Sacramento Medical Center, Mather, CA
Background/Purpose: Tissue-resident memory T cells (TRM) cells can drive localized, recurrent inflammation. TRM are site-specific T cells that take up long-term residence in peripheral tissues…
Abstract Number: 0202 • ACR Convergence 2024
Survival in Patients with Rheumatoid Arthritis and Early-Stage Colorectal, Lung, or Prostate Cancer Receiving Tumor Necrosis Factor Alpha Inhibitors
Maria Suarez-Almazor¹, Juan Ruiz², Xiudong Lei¹, Hui Zhao¹, Suja Rajan³, Heather Lin¹ and Sharon Giordano¹, ¹MD Anderson Cancer Center, Houston, TX, ²MD Anderson, Houston, TX, ³The University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: There is concern about the use of tumor necrosis factor inhibitors (TNFi) in patients with early cancer given their immunosuppressant effects. Few studies have…
Abstract Number: 0310 • ACR Convergence 2024
I-CARE Program: Interest of Multidisciplinary Systematic Screening Program for Comorbidities for Patients Suffering from Arthritis Rheumatoid DiseasE: A Real Life Study
Amine Mouamnia, Armentieres Hospital Center, Armentieres, France
Background/Purpose: Inflammatory and auto-immune disease are associated to comordities. Indeed, patients suffering from arthritis rheumatoid disease (ARD) such as rheumatoid arthritis (RA), polymyalgia rheumatica (PMR)…
Abstract Number: 0449 • ACR Convergence 2024
Evaluating Premenstrual Dysphoric Disorder in Women with Rheumatoid Arthritis and Healthy Female Subjects
Ana Cecilia Bardan-Inchaustegui¹, Iris Jazmín Colunga Pedraza², Rosa Icela Arvizu-Rivera², Gisela Garcia-Arellano³, Griselda Serna-Peña⁴, Maria F. Elizondo-Benitez⁵, Aleydis Gonzalez Melendez², Fernanda Massiel Garcia⁶ and Dionicio Galarza-Delgado⁷, ¹Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³Hospital Universitario \"Dr. José Eleuterio González\", Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", UANL, Monterrey, Mexico, ⁵Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁶Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico, ⁷UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Premenstrual dysphoric disorder (PMDD), a severe form of premenstrual syndrome, is classified as a psychiatric disorder characterized by moderate to severe physical, affective, or…
Abstract Number: 0471 • ACR Convergence 2024
Understanding the Role of the Complement System in Insulin Resistance and Metabolic Syndrome in Patients with Rheumatoid Arthritis
Jose Viotti-Serra¹, Maria Garcia-Gonzalez², Fuensanta Gomez-Bernal¹, Juan Carlos Quevedo-Abeledo³, Miguel Angel Gonzalez-Gay⁴ and ivan Ferraz-Amaro⁵, ¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ²Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, ⁴University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain
Background/Purpose: The complement (C) system has been associated with the etiopathogenesis of rheumatoid arthritis (RA). Insulin resistance (IR) and metabolic syndrome are prevalent among RA…
Abstract Number: 0488 • ACR Convergence 2024
Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis
Pablo Martínez Calabuig¹, Elena Grau García², Samuel Leal Rodriguez², Ernesto Tovar Sugrañes³, José Ivorra-Cortés⁴, Carmen Riesco Barcena³, Anderson Huaylla Quispe³, Laura Mas Sánchez⁵, Pablo Muñoz Martínez⁶, Daniel Ramos Castro³, Alba Torrat noves⁷, Iago Alcantara Alvarez⁸, Belén Villanueva Mañés⁸, Miguel Simeo Vinaixa⁸, Andrés Pérez Hurtado³ and Jose A Román-Ivorra⁹, ¹HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, ²HUP La Fe, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Spain, ⁴Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁵Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ⁶Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ⁷Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁹Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease where the presence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (antiCCP) has been associated to…
Abstract Number: 0505 • ACR Convergence 2024
UseofaMolecularSignatureResponseClassifiertoPredictInadequateResponsetoTNFiResultsinFewer Patients Prescribed TNFi
George Karpouzas¹, Lixia Zhang², Mark Zielinski², Brian Cheng² and Sherry Guardiano³, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Scipher Medicine Corporation, Waltham, MA, ³Scipher Medicine Corporation, Keene, NH
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with…
Abstract Number: 0522 • ACR Convergence 2024
Hematological Impact Assessment of Tofacitinib, Baricitinib, and Upadacitinib in Rheumatoid Arthritis Treatment
Soo Min Ahn, Mi-Ra Cho, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo and Seokchan Hong, Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Janus kinase (JAK) inhibitors' introduction has significantly revolutionized the therapeutic landscape, notably influencing the management strategies for rheumatoid arthritis (RA). To compare the effects…
Abstract Number: 0678 • ACR Convergence 2024
Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually
Oliver Distler¹, Margarida Alves², Gerrit Toenges³ and Anna-Maria Hoffmann-Vold⁴, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ²Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ³Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁴Oslo University Hospital, Oslo, Norway
Background/Purpose: There is no consensus on the frequency of monitoring of patients with autoimmune disease-related interstitial lung diseases (ILDs), but a frequency of 1 year…
Abstract Number: 0871 • ACR Convergence 2024
Disease-associated Central Nervous System Activation Predicts Good Clinical Response to Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis Patients – “The PreCePRA Study”
Juergen Rech¹, Prof. Dr. Andreas Hess², Koray Tascilar¹, Dr. Hannah Schenker³, verena schönau¹, Marina Sergeeva², Jutta Prade², Silke Kreitz², Mageshva Sulvakumar², Laura Konerth², Sandra Strobelt², Matthias Englbrecht⁴, Prof. Dr. Dr. Axel Hueber⁵, Eugen Feist⁶, Prof. Dr. Mario Zaiss¹, Gerd Burmester⁷, Frank Behrens⁸, Dr. Michaela Koehm⁹, Prof. Dr. Christoph Baerwald¹⁰, Dr. Stephanie Finzel¹¹, Dr. Arnd Kleyer¹², Prof. Dr. Reinhard Voll¹¹, Dr. Julie Roesch¹³, Prof. Dr. Arnd Doerfler¹³, Prof. Dr. Nemanja Damjanov¹⁴, Prof. José António P. Da Silva¹⁵ and Georg Schett¹⁶, ¹Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ²Institute for Experimental Pharmacology FAU Erlangen-Nürnberg, Erlangen, Germany, ³Department of Internal Medicine 3 - Rheumatology and Immunology, Department of Internal Medicine 1 - Gastroenterology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Freelance Healthcare Data Scientist, Eckental, ⁵Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, + Rheumatologie, Klinik für Innere Medizin 5, Klinikum Nürnberg Nord, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Deutschland, Erlangen, Germany, ⁶Department of Rheumatology, Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Gommern, Germany, ⁷Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁸University Hospital Goethe University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ⁹Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, ¹⁰Medizinische Klinik III - Bereich Rheumatologie, Liebigstraße 20, 04103 Leipzig, Leipzig, Germany, ¹¹Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Hugstetterstraße 55, 79106 Freiburg, Freiburg, Germany, ¹²Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany; Charité - Universitätsmedizin Berlin Med. Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie Berlin, Erlangen, Germany, ¹³Department of Neuroradiology, Friedrich - Alexander - Universitaet Erlangen - Nuernberg and Universitaetsklinikum Erlangen , Erlangen , Germany, Erlangen, Germany, ¹⁴Belgrade University School of Medicine, Institute Institute of Rheumatology, Belgrade, Belgrade, Serbia, ¹⁵Head of Department Reumatologia. Hospitais da Universidade (SRHUC), Coimbra, Portugal, ¹⁶Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Rheumatoid arthritis (RA) is an chronic inflammatory disease that is frequently treated with tumor necrosis factor inhibitors (TNFi). Little is known about predictors of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].